CG Oncology | 8-K:重大事件
CG Oncology | 4:持股變動聲明-高管 Patterson Joshua F.
CG Oncology | 3:首次持股聲明-高管 Patterson Joshua F.
CG Oncology | 8-K:CG Oncology公佈2024年第一季度財務業績並提供業務最新情況
CG Oncology | 10-Q:季度報表
CG Oncology | 8-K:重大事件
CG Oncology | SC 13G/A:超過5%持股股東披露文件(修正)-Xiangmin Cui(8.2%),Decheng Capital Global Life Sciences Fund IV, L.P.(7.4%)等
CG Oncology | 4/A:持股變動聲明(修正)-股東 Decheng Capital Global Life Sciences Fund IV, L.P.
CG Oncology | 10-K:年度報表
CG Oncology | SC 13G:超過5%持股股東披露文件-Kissei Pharmaceutical Co., Ltd.(5.3%)
CG Oncology | 8-K:重大事件
CG Oncology | SC 13G:超過5%持股股東披露文件-TCG Crossover GP I, LLC(5.4%),TCG Crossover Fund I, L.P.(5.4%)等
CG Oncology | SC 13G:超過5%持股股東披露文件-Xiangmin Cui(7.6%),Decheng Capital Global Life Sciences Fund IV, L.P.(6.9%)等
CG Oncology | SC 13G:超過5%持股股東披露文件-Patrick G. Enright(7.0%),Juliet Tammenoms Bakker(7.0%)等
CG Oncology | SC 13G:超過5%持股股東披露文件-James Tananbaum (“Tananbaum”)(5.7%),Foresite Capital Fund VI, L.P. (“FCF VI”)(3.2%)等
CG Oncology | 4:持股變動聲明-高管 Kasturi Vijay
CG Oncology | 4:持股變動聲明-高管 Roche Corleen M.
CG Oncology | 4:持股變動聲明-董事 Song Hong Fang
CG Oncology | 4:持股變動聲明-股東 Decheng Capital Global Life Sciences Fund IV, L.P.
CG Oncology | 8-K:重大事件
暫無數據